# Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

Source: https://onco.cc/trials/nct05874414/  
OnCo record `nct05874414` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Trametinib in biliary tract cancer, run by Genfit, now recruiting.

## Summary

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma is a phase 1/2 interventional study registered as NCT05874414 by Genfit, with 98 participants planned, started 2023-08-21 and due to reach its primary completion in 2027-12. Interventions recorded: GNS561 + Trametinib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05874414
- Phase: 1/2
- Setting: Phase 1b/2a Study of GNS561 in Combination With Trametinib in Advanced KRAS Mutated Cholangiocarcinoma
- Sponsor: Genfit
- Enrolled: 98

## Sources

- ClinicalTrials.gov NCT05874414: https://clinicaltrials.gov/study/NCT05874414

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/)
- drugs: [Trametinib](https://onco.cc/drugs/trametinib/)

---
JSON: https://onco.cc/api/v1/entities/nct05874414.json